Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
News Oct 04, 2012
Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline. Currently over 100 pharmaceutical and fine chemical companies in 17 countries have used the Gentronix proprietary GreenScreen HC assay technology as part of their genotoxicity profiling strategy.
“Gentronix is delighted to be working with Kowa in the Japanese market. We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates.” (John Nicholson, Gentronix CEO)
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE